James P. Rizzi
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)Pear Therapeutics (United States)(US)Cellerant Therapeutics (United States)(US)
Publications by Year
Research Areas
Acute Myeloid Leukemia Research, Cancer, Hypoxia, and Metabolism, Chronic Myeloid Leukemia Treatments, Histone Deacetylase Inhibitors Research, Epigenetics and DNA Methylation
Most-Cited Works
- → Targeting renal cell carcinoma with a HIF-2 antagonist(2016)704 cited
- → On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models(2016)448 cited
- → A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma(2016)316 cited
- → Topology of the pore-region of a K+ channel revealed by the NMR-derived structures of scorpion toxins(1995)254 cited
- → 3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma(2019)202 cited
- → The Signature Sequence of Voltage-gated Potassium Channels Projects into the External Vestibule(1996)128 cited